{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:20:02Z","timestamp":1790295602189,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK-111378, DK122056"],"award-info":[{"award-number":["DK-111378, DK122056"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid associated with nonalcoholic steatohepatitis (NASH). Immune cell-driven inflammation is a key determinant of NASH progression. Macrophages, monocytes, NK cells, T cells, NKT cells, and B cells variably express S1P receptors from a repertoire of 5 receptors termed S1P<jats:sub>1<\/jats:sub> \u2013 S1P<jats:sub>5<\/jats:sub>. We have previously demonstrated that non-specific S1P receptor antagonism ameliorates NASH and attenuates hepatic macrophage accumulation. However, the effect of S1P receptor antagonism on additional immune cell populations in NASH remains unknown. We hypothesized that S1P receptor specific modulation may ameliorate NASH by altering leukocyte recruitment. A murine NASH model was established by dietary feeding of C57BL\/6 male mice with a diet high in fructose, saturated fat, and cholesterol (FFC) for 24 weeks. In the last 4 weeks of dietary feeding, the mice received the S1P<jats:sub>1,4,5<\/jats:sub> modulator Etrasimod or the S1P<jats:sub>1<\/jats:sub> modulator Amiselimod, daily by oral gavage. Liver injury and inflammation were determined by histological and gene expression analyses. Intrahepatic leukocyte populations were analyzed by flow cytometry, immunohistochemistry, and mRNA expression. Alanine aminotransferase, a sensitive circulating marker for liver injury, was reduced in response to Etrasimod and Amiselimod treatment. Liver histology showed a reduction in inflammatory foci in Etrasimod-treated mice. Etrasimod treatment substantially altered the intrahepatic leukocyte populations through a reduction in the frequency of T cells, B cells, and NKT cells and a proportional increase in CD11b<jats:sup>+<\/jats:sup> myeloid cells, polymorphonuclear cells, and double negative T cells in FFC-fed and control standard chow diet (CD)-fed mice. In contrast, FFC-fed Amiselimod-treated mice showed no changes in the frequencies of intrahepatic leukocytes. Consistent with the improvement in liver injury and inflammation, hepatic macrophage accumulation and the gene expression of proinflammatory markers such as <jats:italic>Lgals3<\/jats:italic> and <jats:italic>Mcp-1<\/jats:italic> were decreased in Etrasimod-treated FFC-fed mice. Etrasimod treated mouse livers demonstrated an increase in non-inflammatory (<jats:italic>Marco<\/jats:italic>) and lipid associated (<jats:italic>Trem2<\/jats:italic>) macrophage markers. Thus, S1P<jats:sub>1,4,5<\/jats:sub> modulation by Etrasimod is more effective than S1P<jats:sub>1<\/jats:sub> antagonism by Amiselimod, at the dose tested, in ameliorating NASH, likely due to the alteration of leukocyte trafficking and recruitment. Etrasimod treatment results in a substantial attenuation of liver injury and inflammation in murine NASH.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1130184","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:30:21Z","timestamp":1682051421000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Modulating sphingosine 1-phosphate receptor signaling skews intrahepatic leukocytes and attenuates murine nonalcoholic steatohepatitis"],"prefix":"10.3389","volume":"14","author":[{"given":"Chieh-Yu","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanta","family":"Barrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanditha","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Fredrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejasav S.","family":"Sehrawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjali","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier S.","family":"Revelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmeet","family":"Malhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M063412","article-title":"Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1alpha-dependent manner","volume":"57","author":"Kakazu","year":"2016","journal-title":"J Lipid Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","article-title":"Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis","volume":"155","author":"Musso","year":"2018","journal-title":"Gastroenterology."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15058591","article-title":"Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation","volume":"15","author":"Peverill","year":"2014","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3390\/ijms19030722","article-title":"Divergent role of sphingosine 1-phosphate in liver health and disease","volume":"19","author":"Kleuser","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4062\/biomolther.2016.160","article-title":"Sphingosine 1-phosphate receptor modulators and drug discovery","volume":"25","author":"Park","year":"2017","journal-title":"Biomol Ther (Seoul)."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76369","article-title":"Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy","volume":"125","author":"Proia","year":"2015","journal-title":"J Clin Invest."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i13.1725","article-title":"Is there a role for adaptive immunity in nonalcoholic steatohepatitis","volume":"7","author":"Sutti","year":"2015","journal-title":"World J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00222.2016","article-title":"Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis","volume":"312","author":"Mauer","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"eaar5551","DOI":"10.1126\/science.aar5551","article-title":"Sphingosine 1-phosphate: lipid signaling in pathology and therapy","volume":"366","author":"Cartier","year":"2019","journal-title":"Science."},{"key":"B13","doi-asserted-by":"publisher","first-page":"13p","DOI":"10.1111\/bph.13641","article-title":"Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk","volume":"174","author":"Maeda","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00145.2011","article-title":"Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition","volume":"301","author":"Charlton","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1404","article-title":"Characterization of cellular sources and circulating levels of extracellular vesicles in a dietary murine model of nonalcoholic steatohepatitis","volume":"3","author":"Li","year":"2019","journal-title":"Hepatol Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.442954","article-title":"C\/EBP homologous protein-induced macrophage apoptosis protects mice from steatohepatitis","volume":"288","author":"Malhi","year":"2013","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/BF02618288","article-title":"Mouse liver cell culture","volume":"17","author":"Klaunig","year":"1981","journal-title":"I. Hepatocyte isolation. In Vitro."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03815.x","article-title":"Isolation of murine intrahepatic immune cells employing a modified procedure for mechanical disruption and functional characterization of the b, T and natural killer T cells obtained","volume":"155","author":"Blom","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0590-4","article-title":"Single-cell transcriptomics of 20 mouse organs creates a tabula muris","volume":"562","author":"Tabula Muris","year":"2018","journal-title":"Nature."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260307","article-title":"Ki-67 expression during rat liver regeneration after partial hepatectomy","volume":"26","author":"Gerlach","year":"1997","journal-title":"Hepatology."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgq277","article-title":"Constitutive active\/androstane receptor promotes hepatocarcinogenesis in a mouse model of non-alcoholic steatohepatitis","volume":"32","author":"Takizawa","year":"2011","journal-title":"Carcinogenesis."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1381","article-title":"Liver proliferation is an essential driver of fibrosis in mouse models of nonalcoholic fatty liver disease","volume":"3","author":"Cast","year":"2019","journal-title":"Hepatol Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0165-6147(99)01419-4","article-title":"FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation","volume":"21","author":"Brinkmann","year":"2000","journal-title":"Trends Pharmacol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.31.1_supplement.993.11","article-title":"Etrasimod (APD334), an oral, next-generation sphingosine-1-Phosphate receptor modulator inhibits the development of colitis in lymphoid-null mice injected with colitogenic CD4+T cells","volume":"31","author":"Adams","year":"2017","journal-title":"FASEB J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12836","article-title":"Sphingosine-1-phosphate receptors and innate immunity","volume":"20","author":"Bryan","year":"2018","journal-title":"Cell Microbiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00883","article-title":"Human double-negative regulatory T cells selectively suppress mTOR signaling and metabolic reprogramming of conventional T cells","volume":"47","author":"Haug","year":"2017","journal-title":"Eur J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/ecco-jcc\/jjw013","article-title":"Galectin-3 plays an important pro-inflammatory role in the induction phase of acute colitis by promoting activation of NLRP3 inflammasome and production of IL-1\u03b2 in macrophages","volume":"10","author":"Simovic Markovic","year":"2016","journal-title":"J Crohns Colitis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.cell.2016.10.025","article-title":"Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance","volume":"167","author":"Li","year":"2016","journal-title":"Cell."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2014.06.016","article-title":"Free fatty acids and IL-6 induce adipocyte galectin-3 which is increased in white and brown adipose tissues of obese mice","volume":"69","author":"Krautbauer","year":"2014","journal-title":"Cytokine."},{"key":"B30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.08.002","article-title":"Liver macrophages in health and disease","volume":"55","author":"Guilliams","year":"2022","journal-title":"Immunity."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01706","article-title":"Sphingosine-1-Phosphate and macrophage biology-how the sphinx tames the big eater","volume":"10","author":"Weigert","year":"2019","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00400","article-title":"Frontiers in drug research and development for inflammatory bowel disease","volume":"8","author":"Curro","year":"2017","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"8606878","DOI":"10.1155\/2016\/8606878","article-title":"Sphingosine-1-Phosphate signaling in immune cells and inflammation: roles and therapeutic potential","volume":"2016","author":"Aoki","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B35","first-page":"121","article-title":"Regulation of immune cell migration by sphingosine-1-Phosphate","volume":"61","author":"Kumar","year":"2015","journal-title":"Cell Mol Biol (OMICS)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting sphingosine-1-Phosphate signaling in immune-mediated diseases: beyond multiple sclerosis","volume":"81","author":"P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nri2400","article-title":"The alliance of sphingosine-1-phosphate and its receptors in immunity","volume":"8","author":"Rivera","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"12p","DOI":"10.1016\/S1474-4422(16)30192-2","article-title":"Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"15","author":"Arnold","year":"2016","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1130184\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:30:28Z","timestamp":1682051428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1130184\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2023.1130184"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1130184","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1130184"}}